The Blueprint Programmed Death Ligand 1 (PD-L1) Immunohistochemistry (IHC) Assay Comparison Project is an industrial-academic collaborative partnership to provide information on the analytical and clinical comparability of four PD-L1 IHC assays used in clinical trials.Ī total of 39 NSCLC tumors were stained with four PD-L1 IHC assays (22C3, 28-8, SP142, and SP263), as used in the clinical trials. 13 Department of Pathology, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen, Scotland.12 Department of Pathology, University Health Network, Princess Margaret Cancer Centre and University of Toronto, Ontario, Canada.11 Carolinas Pathology Group, Carolinas HealthCare System, Charlotte, North Carolina. 10 AstraZeneca, Cambridge, United Kingdom.9 Genentech, Oncology Biomarkers Development, South San Francisco, California.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |